Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database

Research output: Contribution to journalArticlepeer-review

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{0d7479181fad46b1bd9026140bbee9a6,
title = "Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database",
abstract = "Background: Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension and cardiovascular events. Previous studies have suggested an increased risk of non-alcoholic fatty liver disease (NAFLD) in PCOS and implicated androgen excess as a potential driver.Methods and findings: We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, BMI- and location-matched control women registered from January 2000 to May 2016. In two independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n=71,061) and sex hormone-binding globulin (SHBG; n=49,625). We used multivariate Cox models to estimate Hazard Ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR=2·23, 95%CI 1·86-2·66, p<0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR=2.30, 95%CI 1.16-4.53, p=0.017 for 3-3.49 nmol/L and HR=2·40, 95%CI 1·24-4·66, p=0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR=4.75, 95%CI 2.44-9.25, p<0.001 for 20-29.99 nmol/L and HR=4·98, 95%CI 2·45-10·11, p<0.001 for <20 nmol/L). Limitations include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and the absence of data on laboratory assays used to measure serum androgens. Conclusions: We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.",
author = "Balachandran Kumarendran and Michael O'Reilly and Konstantinos Manolopoulos and Konstantinos Toulis and Krishna Gokhale and Alice Sitch and Wijeyaratne, {Chandrika N.} and Aravinthan Coomarasamy and Wiebke Arlt and Krishnarajah Nirantharakumar",
year = "2018",
month = mar,
day = "28",
doi = "10.1371/journal.pmed.1002542",
language = "English",
volume = "15",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Public Library of Science (PLOS)",
number = "3",

}

RIS

TY - JOUR

T1 - Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women

T2 - a longitudinal study based on a United Kingdom primary care database

AU - Kumarendran, Balachandran

AU - O'Reilly, Michael

AU - Manolopoulos, Konstantinos

AU - Toulis, Konstantinos

AU - Gokhale, Krishna

AU - Sitch, Alice

AU - Wijeyaratne, Chandrika N.

AU - Coomarasamy, Aravinthan

AU - Arlt, Wiebke

AU - Nirantharakumar, Krishnarajah

PY - 2018/3/28

Y1 - 2018/3/28

N2 - Background: Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension and cardiovascular events. Previous studies have suggested an increased risk of non-alcoholic fatty liver disease (NAFLD) in PCOS and implicated androgen excess as a potential driver.Methods and findings: We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, BMI- and location-matched control women registered from January 2000 to May 2016. In two independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n=71,061) and sex hormone-binding globulin (SHBG; n=49,625). We used multivariate Cox models to estimate Hazard Ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR=2·23, 95%CI 1·86-2·66, p<0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR=2.30, 95%CI 1.16-4.53, p=0.017 for 3-3.49 nmol/L and HR=2·40, 95%CI 1·24-4·66, p=0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR=4.75, 95%CI 2.44-9.25, p<0.001 for 20-29.99 nmol/L and HR=4·98, 95%CI 2·45-10·11, p<0.001 for <20 nmol/L). Limitations include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and the absence of data on laboratory assays used to measure serum androgens. Conclusions: We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.

AB - Background: Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension and cardiovascular events. Previous studies have suggested an increased risk of non-alcoholic fatty liver disease (NAFLD) in PCOS and implicated androgen excess as a potential driver.Methods and findings: We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, BMI- and location-matched control women registered from January 2000 to May 2016. In two independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n=71,061) and sex hormone-binding globulin (SHBG; n=49,625). We used multivariate Cox models to estimate Hazard Ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR=2·23, 95%CI 1·86-2·66, p<0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR=2.30, 95%CI 1.16-4.53, p=0.017 for 3-3.49 nmol/L and HR=2·40, 95%CI 1·24-4·66, p=0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR=4.75, 95%CI 2.44-9.25, p<0.001 for 20-29.99 nmol/L and HR=4·98, 95%CI 2·45-10·11, p<0.001 for <20 nmol/L). Limitations include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and the absence of data on laboratory assays used to measure serum androgens. Conclusions: We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.

U2 - 10.1371/journal.pmed.1002542

DO - 10.1371/journal.pmed.1002542

M3 - Article

VL - 15

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 3

M1 - e1002542

ER -